"FDA Approves Zuranolone: A Breakthrough Pill for Postpartum Depression"

The US FDA has approved the first pill specifically designed to treat postpartum depression, providing a more convenient and fast-acting medication option for severe cases. Postpartum depression affects approximately one in seven women who have given birth, but 50% of cases go undiagnosed due to gaps in screening and reporting. The newly approved pill, zuranolone, works by improving levels of allopregnanolone, a neuroactive steroid that can decrease after pregnancy. It has been found to take effect within three days and have a lasting positive impact. However, experts caution that the medication may not be suitable for mild to moderate cases and stress the importance of addressing structural factors and utilizing other tools like therapy.